Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Who Skipped the Bloody Market? Why Gilead Embarked on Galapagos NV Drug Filgotonib?

January 4, 2016 0

The market looks like angry, probably very angry, as stocks are in a severe selloff mood. …

Prohost Letter #389

January 2, 2016 0

Prohost Letter #389 Happy New Year 2016 Wishing You Good Health Peace of Mind Love And …

Array Rallies on Successful NEMO Trial Results of Binetinib on NRAS-Mutant Melanoma

December 16, 2015 0

When you do your due diligence, you do not lose your faith in what you believed …

Halozyme PEGPH20 Improves the Efficacy of Halavan in Triple Negative Breast Cancer

December 10, 2015 0

Halozyme Therapeutics (HALO) and Eisai Inc. presented a scientific poster entitled, “Pegylated Recombinant Human Hyaluronidase PH20 (PEGPH20) Enhances …

Xoma: Good News for the Firm We Love and Hate But We Never Divorce

December 2, 2015 0

XOMA Announces License Agreement with Novo Nordisk for XMetA Program in Diabetes – Novo Nordisk acquires …

Prohost Letter #388

December 2, 2015 0

Prohost Letter #388 TOPICS - 1. AN INDISPENSABLE SHORT INTRODUCTION 2. GENE EDITING 3. GENE THERAPY …

BioMarin: What Happened During the FDA Committee Meeting?

November 25, 2015 0

In our yesterday’s article asking about how the FDA advisory committee has to vote regarding Biomarin …

BioMarin: The DMD Drug and the FDA Committee Options

November 24, 2015 0

Today, the FDA advisory panel will discuss BioMarin (BMRN) product drisapersen for Duchenne muscular dystrophy based on documents released …

Vertex: Orkambi Approved In Europe. What Vertex Is Doing to Further improve CF Treatments

November 20, 2015 0

Europe Approves Orkambi® The European Commission has granted Marketing Authorization for Orkambi® (lumacaftor/ivacaftor), for cystic fibrosis …

Ziopharm Wages Its Own War on Brain Cancer

November 19, 2015 0

When we hear about a new approach that promises bringing in hopefulness in patients diagnosed with …

Aimmune Therapeutics: Oral Peanut Desensitization Treatment is Promising

November 11, 2015 0

Food allergies are bad, significant, dangerous and growing in the U.S. and the rest of the …

Exelixis Will Begin Reaping the Fruits

November 10, 2015 0

Exelixis (EXEL) received the first of the great news we expected to hear. Today, the U.S. Food …

Prohost Letter #387

November 10, 2015 0

Prohost Letter #387 Topic of the Week DUCHENNE MUSCULAR DYSTROPHY Which Firms Will Get It Right …

Incyte is a Great Biotech Firm

November 7, 2015 0

To shareholders who were stupefied with an instigated selloff of Incyte’s (INCY) stock today, we say …

Dyax Acquisition and Biocryst Future

November 3, 2015 0

– Shire to Acquire Dyax for $5.9million and some possible extras. – Angioedema market has treatments …

Prohost Letter #386

November 2, 2015 0

Prohost Letter #386 An Evaluation of Prohost Picks and Some Other Interesting Biotechnology Companies (Part 2) …

Another Durable Botulinum Toxin with Many Advantages over Botox

October 29, 2015 0

Another Durable Botulinum Toxin with Many Advantages REVANCE THERAPEUTICS As per its self- described profile, Revance …

Cytokinetics Heart Failure Drug Worked

October 27, 2015 0

POSITIVE TOP-LINE RESULTS FROM A PHASE 2 TRIAL OF OMECAMTIV MECARBIL IN PATIENTS WITH CHRONIC HEART FAILURE …

URGENT BREAKING NEWS

October 22, 2015 0

The FDA issued a warning that hepatitis C treatment Viekira Pak and Technivie can cause serious …

The Stream of Exelixis Good News Is Real

October 22, 2015 0

– Exelixis submitted rolling NDA for cabozantinib. – Exelixis plans to complete the submission in the …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

Who Skipped the Bloody Market? Why Gilead Embarked on Galapagos NV Drug Filgotonib?

Prohost Letter #389

Array Rallies on Successful NEMO Trial Results of Binetinib on NRAS-Mutant Melanoma

Halozyme PEGPH20 Improves the Efficacy of Halavan in Triple Negative Breast Cancer

Xoma: Good News for the Firm We Love and Hate But We Never Divorce

Prohost Letter #388

BioMarin: What Happened During the FDA Committee Meeting?

BioMarin: The DMD Drug and the FDA Committee Options

Vertex: Orkambi Approved In Europe. What Vertex Is Doing to Further improve CF Treatments

Ziopharm Wages Its Own War on Brain Cancer

Aimmune Therapeutics: Oral Peanut Desensitization Treatment is Promising

Exelixis Will Begin Reaping the Fruits

Prohost Letter #387

Incyte is a Great Biotech Firm

Dyax Acquisition and Biocryst Future

Prohost Letter #386

Another Durable Botulinum Toxin with Many Advantages over Botox

Cytokinetics Heart Failure Drug Worked

URGENT BREAKING NEWS

The Stream of Exelixis Good News Is Real